EMQN statement: impact of COVID-19 pandemic on EQA timetables

2 weeks ago

We are aware that the coronavirus (COVID-19) outbreak is putting sustained pressure on genomic testing services globally. Therefore, EMQN has issued the following statement:

The EQA distributions planned for May and June 2020 have been postponed

 

The schemes affected are:

  • Molecular testing in Colorectal cancer
  • Molecular testing in Lung Cancer
  • Molecular testing for Melanoma
  • Oncogene panel testing
  • Microsatellite instability testing (pilot)
  • Pharmacogenetics panel testing
  • DNA sequencing – Sanger
  • Postnatal constitutional CNV detection [Array]

The samples will be sent later in the year. EMQN will confirm the new EQA timetable with all registered laboratories at least two months prior to EQA sample distribution date.

We understand that this delay might have an impact on the accreditation status for some laboratories. We have therefore prepared a letter of support which our laboratories can show to their accreditation provider to explain why EQA participation certificates may be delayed in 2020. To download a copy of the letter, please login to the respective 2020 scheme page via your EMQN website account.

We will review the situation regularly and publish updates on our website, and via our social media channels.

The EMQN team are contactable at office@emqn.org  and will respond to any customers as quickly as possible. Thank you for your continued support.

The EMQN Team.

Next: AZ sponsor cfDNA testing EQA scheme
Translate »